The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine ... Lilly's Humalog (insulin lispro) – will be priced at no more than $30 per vial and no more than ...
"The 10 mL [millilter] vials of Humalog® and Insulin Lispro Injection are or will be temporarily out of stock at wholesalers ...
and in its Q3 results Sanofi said US revenues from Lantus were down 15.5% in the quarter to $1.123 billion. Admelog has also been approved in Europe as a biosimilar under the name Insulin lispro ...
Hosted on MSN11mon
Eli Lilly warns 2 of its insulin products may be out of stockThe company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro Injection medications. Eli Lilly said the medications are or will be "temporarily out of stock at ...
Merilog is available in a 3 mL prefilled pen and a 10 mL vial ... with the other two insulin U.S. giants to lower the price of its best-selling insulin product, Lantus (insulin glargine), by ...
A 10 ml vial of Sanofi's long-acting insulin Lantus first hit the US market at $34.81 a vial in 2001, according to data from Truven Health Analytics. Since 2014, the last time Sanofi raised the ...
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback